Company intelligence / Profile preview
Evecxia Therapeutics
Research Triangle Park, North Carolina, United Statesevecxia.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Evecxia has completed Phase 1 trials for both EVX-101 and EVX-301 with favorable safety, tolerability, and pharmacokinetic/pharmacodynamic results. EVX-101 demonstrated the ability to provide sustained and adequate 5-HTP exposure while ensuring safety and tolerability. EVX-301 showed excellent safety and tolerability with evidence of fast-onset brain serotonin activation. A Phase 2 study of adjunctive EVX-101 in depression patients with inadequate response to first-line SSRI/SNRI antidepressants is expected to commence enrollment in late 2024.
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecules (5-HTP-based drugs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Duke University School of MedicineTempusQuotient Sciences
Beyond the preview
Go deeper on Evecxia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evecxia Therapeutics.